Positive outlook for AstraZeneca's Recentin

6 April 2008

AstraZeneca's Recentin (AZD2171) plus FOLFOX4 will earn a 10% patient share of the first-line stage IV colorectal cancer market in the USA by 2016. Additionally, oncologists indicate that they would prescribe this combination to 33% of their patients in the first-line setting for stage IV colorectal cancer, forecasts Decision Resources.

"Although oncologists interviewed are eager to prescribe Recentin plus FOLFOX4, competition from the established Avastin [bevacizumab] will limit patient share," said Marcus Hoyle, an analyst at Decision Resources. "According to oncologists interviewed, physicians are gaining familiarity and comfort with prescribing Avastin in the first-line setting, limiting the uptake of emerging agents," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight